-- Expands Aastrom's Cell Production Products Business --

Aastrom Biosciences, Inc. Reports Fourth Quarter Financial Results Ann Arbor, Michigan, August 26, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today financial results for the fourth quarter and fiscal year ended June 30, 2003. The Company also reported significant achievements

-- IND Approval Key Milestone for Aastrom's Stem Cell Product Program for Tissue Generation --

-- Study Expands Aastrom's Tumor Antigen Primed Vaccine Approach to Ovarian Cancer --

-- Study Marks Aastrom's Entry into Vascular Regeneration Marketplace --

Herbert S. Schwartz, M.D. Appointed to Aastrom Biosciences' Technology Review Board Ann Arbor, Michigan, October 14, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced the appointment of Herbert S. Schwartz, M.D. to its Technology Review Board (TRB). Dr.

Aastrom Biosciences to Present at Fifth Annual Rodman & Renshaw Techvest Healthcare Conference Ann Arbor, Michigan, October 17, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that its President and CEO, R. Douglas Armstrong, Ph.D., will present at the Fifth Annual Rodman &

-- Program Offers Shareholders Exclusive Investment Opportunity --

-- Company Prepares to Enter Clinical Trials of Bone Graft Product --

Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, November 12, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that it will hold an investor conference call on Friday, November 14, 2003 at 10:00 a.m. EST. The purpose of the call will be to bring